Dayvigo-话题@MedSci

#Dayvigo#

4篇内容 | 702人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, objectTitle=卫材在日本推出新型抗失眠药Dayvigo（lemborexant）, objectType=article, longId=197186, objectId=ec5319e186eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5319e186eb, replyNumber=0, likeNumber=50, createdTime=2021-03-27, rootId=0, userName=bshuang, userId=d1e223091112, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5319e186eb, moduleTitle=卫材在日本推出新型抗失眠药Dayvigo（lemborexant）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5319e186eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643063, encodeId=546d16430639a, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, objectTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, objectType=article, longId=200038, objectId=5362200038e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5362200038e5, replyNumber=0, likeNumber=53, createdTime=2021-06-05, rootId=0, userName=bshuang, userId=d1e223091112, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5362200038e5, moduleTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5362200038e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643060, encodeId=3f99164306010, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, objectTitle=失眠症治疗迎来曙光：FDA已批准卫材的Dayvigo, objectType=article, longId=185145, objectId=26df1851459f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26df1851459f, replyNumber=0, likeNumber=34, createdTime=2020-08-01, rootId=0, userName=bshuang, userId=d1e223091112, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26df1851459f, moduleTitle=失眠症治疗迎来曙光：FDA已批准卫材的Dayvigo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26df1851459f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1643061, encodeId=5810164306198, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, objectTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, objectType=article, longId=185379, objectId=6b761853e9f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b761853e9f9, replyNumber=0, likeNumber=0, createdTime=2020-07-26, rootId=0, userName=bshuang, userId=d1e223091112, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b761853e9f9, moduleTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b761853e9f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Dayvigo

2020-05-29

bshuang (审核中...)

前往app查看评论内容

#Dayvigo#

卫材在日本推出新型抗失眠药Dayvigo（lemborexant）

2021-03-27

bshuang (审核中...)

前往app查看评论内容

#Dayvigo#

SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性

2021-06-05

bshuang (审核中...)

前往app查看评论内容

#Dayvigo#

失眠症治疗迎来曙光：FDA已批准卫材的Dayvigo

2020-08-01

bshuang (审核中...)

前往app查看评论内容

#Dayvigo#

JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究

2020-07-26

科室
- - 订阅+
  - 更多科室
工具
服务